MX348568B - Compuestos para inhibir la progresión mitótica. - Google Patents

Compuestos para inhibir la progresión mitótica.

Info

Publication number
MX348568B
MX348568B MX2012011396A MX2012011396A MX348568B MX 348568 B MX348568 B MX 348568B MX 2012011396 A MX2012011396 A MX 2012011396A MX 2012011396 A MX2012011396 A MX 2012011396A MX 348568 B MX348568 B MX 348568B
Authority
MX
Mexico
Prior art keywords
compounds
mitotic progression
inhibiting mitotic
inhibiting
cancer
Prior art date
Application number
MX2012011396A
Other languages
English (en)
Spanish (es)
Inventor
F Claiborne Christopher
G Stroud Stephen
B Sells Todd
Original Assignee
Millennium Pharmaceuticals Inc *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39315133&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX348568(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Millennium Pharmaceuticals Inc * filed Critical Millennium Pharmaceuticals Inc *
Publication of MX348568B publication Critical patent/MX348568B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MX2012011396A 2006-11-16 2007-11-14 Compuestos para inhibir la progresión mitótica. MX348568B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85934006P 2006-11-16 2006-11-16
PCT/US2007/023948 WO2008063525A1 (en) 2006-11-16 2007-11-14 Compounds for inhibiting mitotic progression

Publications (1)

Publication Number Publication Date
MX348568B true MX348568B (es) 2017-06-20

Family

ID=39315133

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2012011396A MX348568B (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresión mitótica.
MX2009004670A MX2009004670A (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresion mitotica.
MX2012011398A MX343391B (es) 2006-11-16 2007-11-14 Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina.

Family Applications After (2)

Application Number Title Priority Date Filing Date
MX2009004670A MX2009004670A (es) 2006-11-16 2007-11-14 Compuestos para inhibir la progresion mitotica.
MX2012011398A MX343391B (es) 2006-11-16 2007-11-14 Proceso para la preparación de 5h-pirimido[5,4-d]benzazepina.

Country Status (34)

Country Link
US (7) US8026246B2 (enExample)
EP (4) EP2944639B1 (enExample)
JP (3) JP5102839B2 (enExample)
KR (2) KR101342014B1 (enExample)
CN (2) CN103483343B (enExample)
AR (1) AR064246A1 (enExample)
AT (1) ATE556076T1 (enExample)
AU (1) AU2007322046B2 (enExample)
BR (1) BRPI0718803B8 (enExample)
CA (1) CA2669680C (enExample)
CL (1) CL2007003244A1 (enExample)
CR (3) CR10782A (enExample)
CY (1) CY1112828T1 (enExample)
DK (2) DK2086981T3 (enExample)
EA (1) EA015779B1 (enExample)
ES (3) ES2537451T3 (enExample)
GE (1) GEP20125459B (enExample)
HR (2) HRP20120490T1 (enExample)
IL (1) IL198690A0 (enExample)
MA (1) MA30988B1 (enExample)
MX (3) MX348568B (enExample)
MY (1) MY153243A (enExample)
NO (1) NO343338B1 (enExample)
NZ (3) NZ611898A (enExample)
PH (1) PH12012502057B1 (enExample)
PL (2) PL2086981T3 (enExample)
PT (2) PT2086981E (enExample)
RS (2) RS52313B (enExample)
SG (2) SG176443A1 (enExample)
SI (2) SI2086981T1 (enExample)
TW (1) TWI401255B (enExample)
UA (1) UA94129C2 (enExample)
WO (1) WO2008063525A1 (enExample)
ZA (1) ZA200903279B (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20080120T5 (hr) * 2004-05-14 2012-07-31 Millennium@Pharmaceuticals Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
WO2010065134A1 (en) * 2008-12-05 2010-06-10 Millennium Pharmaceuticals, Inc. 5, 7-dihydro- 6h-pyrimido [ 5, 4-d] [ 1 ] benzazepin-6-thiones as plk inhibitors
WO2010074724A1 (en) * 2008-12-22 2010-07-01 Millennium Pharmaceuticals, Inc. Combination of aurora kinase inhibitors and anti-cd20 antibodies
JO3635B1 (ar) 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها
JO3434B1 (ar) * 2009-07-31 2019-10-20 Millennium Pharm Inc مركبات صيدلانية لمعالجة السرطان وامراض واضطرابات اخري
RU2012140021A (ru) * 2010-02-19 2014-03-27 Миллениум Фармасьютикалз, Инк. КРИСТАЛЛИЧЕСКИЕ ФОРМЫ 4-{[9-ХЛОР-7-(2-ФТОР-6-МЕТОКСИФЕНИЛ)-5Н-ПИРИМИДО[5,4-d][2]БЕНЗАЗЕПИН-2-ИЛ]АМИНО}-2-МЕТОКСИБЕНЗОАТА НАТРИЯ
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
JP5844358B2 (ja) * 2010-06-22 2016-01-13 グラクソスミスクライン エルエルシー ベンゾトリアゾロジアゼピン化合物を含むブロモドメイン阻害剤
UY34114A (es) 2011-06-03 2013-01-03 Millennium Pharm Inc Combinación de inhibidores de mek e inhibidores selectivos de la quiinasa aurora a
US20130303519A1 (en) * 2012-03-20 2013-11-14 Millennium Pharmaceuticals, Inc. Methods of treating cancer using aurora kinase inhibitors
CN103772391A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
EP2976086B1 (en) * 2013-03-22 2020-10-14 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
JP6525474B2 (ja) 2013-12-06 2019-06-05 ミレニアム ファーマシューティカルズ， インコーポレイテッドＭｉｌｌｅｎｎｉｕｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． オーロラキナーゼ阻害剤と抗ｃｄ３０抗体の併用
CA2972076A1 (en) * 2014-12-23 2016-06-30 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
EP3324976A4 (en) 2015-07-21 2019-03-27 Millennium Pharmaceuticals, Inc. ADMINISTRATION OF KINASE AURORA INHIBITOR AND CHEMOTHERAPEUTIC AGENTS
WO2017044567A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
CA2997784A1 (en) 2015-09-09 2017-03-16 Icahn School Of Medicine At Mount Sinai Heterocyclic constrained tricyclic sulfonamides as anti-cancer agents
WO2017146253A1 (ja) 2016-02-26 2017-08-31 公益財団法人がん研究会 Ｈｐ１の機能に着目した抗癌剤のスクリーニング方法及び評価系
AU2017233898B2 (en) 2016-03-15 2022-12-15 Oryzon Genomics, S.A. Combinations of LSD1 inhibitors for use in the treatment of solid tumors
JP6188986B1 (ja) * 2017-03-23 2017-08-30 株式会社ノエビア 時計遺伝子発現量調整剤及びエラスチン産生促進剤
WO2019195658A1 (en) 2018-04-05 2019-10-10 Dana-Farber Cancer Institute, Inc. Sting levels as a biomarker for cancer immunotherapy
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
WO2021041532A1 (en) 2019-08-26 2021-03-04 Dana-Farber Cancer Institute, Inc. Use of heparin to promote type 1 interferon signaling
WO2023196959A1 (en) 2022-04-07 2023-10-12 Eli Lilly And Company Process for making a kras g12c inhibitor
CA3247183A1 (en) 2022-04-08 2023-10-12 Lilly Co Eli TREATMENT METHOD INCLUDING KRAS G12C INHIBITORS AND AURORA A INHIBITORS
KR20250027777A (ko) 2022-06-30 2025-02-27 일라이 릴리 앤드 캄파니 암을 치료하기 위한 kras g12c 억제제
WO2025075211A1 (en) 2023-10-03 2025-04-10 Takeda Pharmaceutical Company Limited Alisertib and paclitaxel for treating small cell lung cancer
WO2025245045A1 (en) 2024-05-21 2025-11-27 The Regents Of The University Of California Methods of treating lung cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4099012A (en) 1975-08-28 1978-07-04 Ciba-Geigy Corporation 2-pyrazolyl-benzophenones
NZ192803A (en) 1979-02-07 1984-08-24 Hoffmann La Roche Pyrimido-2-benzazepines and pharmaceutical compositions
US4481142A (en) 1979-02-07 1984-11-06 Hoffmann-La Roche Inc. Pyrimido-2-benzazepines
US4469633A (en) 1980-05-16 1984-09-04 Hoffmann-La Roche Inc. N-oxides of 5-oxo-1-phenyl-2-benzazepines
EP0273697A3 (en) 1986-12-30 1989-11-29 Merck & Co. Inc. 2-benzazepines with 5- and 6- membered heterocyclic rings
US5166151A (en) 1988-03-25 1992-11-24 Merck & Co., Inc. 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
US5210082A (en) 1991-05-16 1993-05-11 Merck & Co., Inc. 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
TW486480B (en) * 1996-03-08 2002-05-11 Zeneca Ltd Azolobenzazepine derivatives and compositions and method of use thereof
JP2001507349A (ja) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド 縮合多環式２−アミノピリミジン誘導体、それらの製造およびたんぱく質チロシンキナーゼ抑制因子としてのそれらの使用
GB9713087D0 (en) 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
KR100389140B1 (ko) * 1997-09-29 2003-06-25 메이지 세이카 가부시키가이샤 삼환성 트리아졸로벤즈아제핀 유도체 및 그의 제조방법 및항알레르기제
US6277844B1 (en) 1998-09-14 2001-08-21 Sydney Spector Compound for selective treatment of malignant cells by inhibiting cell cycle progression, decreasing Bcl2, and increasing apoptosis
US6417207B1 (en) 1999-05-12 2002-07-09 Nitromed, Inc. Nitrosated and nitrosylated potassium channel activators, compositions and methods of use
DE60039782D1 (de) 1999-12-06 2008-09-18 Ajinomoto Kk Amidinophenylbrenztraubensäure-derivat
CA2432799C (en) 2000-12-21 2008-08-19 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6686352B2 (en) 2001-05-18 2004-02-03 Hoffmann-La Roche Inc. Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives
DE10135457A1 (de) * 2001-07-20 2003-02-06 Adc Automotive Dist Control Optische Sensoranordnung
AU2002328999B8 (en) 2001-08-09 2008-06-05 Actelion Pharmaceuticals Ltd. Novel benzo-fused heterocycles as endothelin antagonists
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
HRP20080120T5 (hr) 2004-05-14 2012-07-31 Millennium@Pharmaceuticals Spojevi i postupci za inhibiciju napredovanja mitoze s pomoću inhibicije aurora kinaze
CA2587427A1 (en) 2004-11-17 2006-05-26 Miikana Therapeutics, Inc. Kinase inhibitors
JP2008526723A (ja) 2004-12-30 2008-07-24 アステックス、セラピューティックス、リミテッド Ｃｄｋ、ｇｓｋ及びオーロラキナーゼの活性を調節するピラゾール誘導体
KR20080083680A (ko) 2005-12-23 2008-09-18 스미스클라인 비참 코포레이션 오로라 키나제의 아자인돌 억제제
EP2054413A2 (en) 2006-08-09 2009-05-06 Millennium Pharmaceuticals, Inc. Pyridobenzazepine compounds and methods for inhibiting mitotic progression
CL2007003244A1 (es) 2006-11-16 2008-04-04 Millennium Pharm Inc Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
JO3635B1 (ar) * 2009-05-18 2020-08-27 Millennium Pharm Inc مركبات صيدلانية صلبة وطرق لانتاجها

Also Published As

Publication number Publication date
ATE556076T1 (de) 2012-05-15
US20110312943A1 (en) 2011-12-22
CA2669680A1 (en) 2008-05-29
PL2086981T3 (pl) 2012-09-28
BRPI0718803A2 (pt) 2013-12-03
MA30988B1 (fr) 2009-12-01
CA2669680C (en) 2012-04-10
US20190031662A1 (en) 2019-01-31
US11958855B2 (en) 2024-04-16
DK2086981T3 (da) 2012-08-06
US8026246B2 (en) 2011-09-27
CN101547924A (zh) 2009-09-30
US20080167292A1 (en) 2008-07-10
AR064246A1 (es) 2009-03-25
NZ611898A (en) 2015-01-30
IL198690A0 (en) 2010-02-17
SG176443A1 (en) 2011-12-29
TWI401255B (zh) 2013-07-11
GEP20125459B (en) 2012-03-26
CY1112828T1 (el) 2016-02-10
CR20140544A (es) 2015-01-12
PH12012502057A1 (en) 2015-09-14
RS52313B (sr) 2012-12-31
SG10201503350TA (en) 2015-06-29
EP2944639B1 (en) 2017-01-04
BRPI0718803B8 (pt) 2021-05-25
EP2497773A1 (en) 2012-09-12
US10836766B2 (en) 2020-11-17
CN103483343B (zh) 2016-06-01
UA94129C2 (ru) 2011-04-11
ES2384123T3 (es) 2012-06-29
AU2007322046B2 (en) 2012-04-05
HK1134672A1 (en) 2010-05-07
CN101547924B (zh) 2013-09-25
PT2497772E (pt) 2015-02-05
CL2007003244A1 (es) 2008-04-04
EP2086981A1 (en) 2009-08-12
RS53788B1 (sr) 2015-06-30
NO343338B1 (no) 2019-02-04
MY153243A (en) 2015-01-29
BRPI0718803B1 (pt) 2020-11-17
KR101110458B1 (ko) 2012-03-13
EP2497772A1 (en) 2012-09-12
MX343391B (es) 2016-11-04
US20210214361A1 (en) 2021-07-15
KR101342014B1 (ko) 2013-12-19
HK1175778A1 (en) 2013-07-12
EP2497772B1 (en) 2014-10-29
EA200970486A1 (ru) 2009-10-30
KR20090091173A (ko) 2009-08-26
US9765076B2 (en) 2017-09-19
CN103483343A (zh) 2014-01-01
PL2497772T3 (pl) 2015-05-29
US9988384B2 (en) 2018-06-05
CR20140154A (es) 2014-07-23
JP5102839B2 (ja) 2012-12-19
ZA200903279B (en) 2010-07-28
SI2086981T1 (sl) 2012-12-31
JP2010510215A (ja) 2010-04-02
CR10782A (es) 2009-06-24
EA015779B1 (ru) 2011-12-30
HRP20120490T1 (hr) 2012-07-31
ES2537451T3 (es) 2015-06-08
EP2944639A1 (en) 2015-11-18
PH12012502057B1 (en) 2018-10-24
HRP20150047T1 (en) 2015-03-13
US20110312942A1 (en) 2011-12-22
DK2497772T3 (en) 2015-01-19
KR20110113210A (ko) 2011-10-14
JP5452811B2 (ja) 2014-03-26
US20240400567A1 (en) 2024-12-05
NZ577042A (en) 2012-03-30
ES2528793T3 (es) 2015-02-12
EP2086981B1 (en) 2012-05-02
NZ597252A (en) 2013-06-28
AU2007322046A1 (en) 2008-05-29
JP2014055166A (ja) 2014-03-27
HK1175777A1 (en) 2013-07-12
SI2497772T1 (sl) 2015-03-31
EP2497773B1 (en) 2015-02-25
MX2009004670A (es) 2009-05-15
PT2086981E (pt) 2012-06-20
TW200829589A (en) 2008-07-16
JP2012006965A (ja) 2012-01-12
NO20091864L (no) 2009-06-15
HK1217699A1 (en) 2017-01-20
US20150166545A1 (en) 2015-06-18
WO2008063525A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
PH12012502057A1 (en) Compounds for inhibiting mitotic progression
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
MY149512A (en) Pyrazolylaminopyridine derivatives useful as kinase inhibitors
WO2006123113A3 (en) Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
WO2007095124A3 (en) Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors
MY148634A (en) Pyridazinone derivatives
TW200604192A (en) Compounds and methods for inhibiting mitotic progression
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
WO2009155121A3 (en) Inhibitors of pi3 kinase
SG179418A1 (en) Inhibitors of the hedgehog pathway
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PT1853588E (pt) Compostos químicos
NZ577916A (en) Cyclopamine analogs
TN2009000049A1 (en) A pyrrolopyrazin as syk-kinase inhibitor
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
MX2010002210A (es) Derivados de catecolamina y profarmacos de los mismos.
MX2009004140A (es) Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa 3.
MX2009011059A (es) Aminopirimidinas utiles como inhibidores de cinasas.
WO2010039668A3 (en) Inhibitors of cyclin kinase inhibitor p21
MX2010004604A (es) Derivados de pirazol como inhibidores de 5-lo.
IL191670A0 (en) Compounds for the inhibition of apoptosis
MX2009012079A (es) Compuestos heterociclicos condensados como inhibidores de proteina cinasas.
MY159181A (en) Use of an anti-cancer compound
EP1905773A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase